Elisabeth Sandoval Little - 13 May 2022 Form 4 Insider Report for Intersect ENT, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 13 May 2022
Net transaction value: -$449,062
SEC form: 4
Accepted by SEC: 16 May 2022, 18:39:02 UTC
Prior SEC filing: 25 Oct 2021
Next SEC filing: 07 Jun 2022
Source filing: View source filing
Reporting owner signature: /s/ Patrick A. Broderick, as Attorney-in-Fact for Elisabeth Sandoval-Little

Key filing fact

Elisabeth Sandoval Little filed Form 4 for Intersect ENT, Inc. on 16 May 2022.

Key facts

This page summarizes Elisabeth Sandoval Little's Form 4 filing for Intersect ENT, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 16 May 2022, 18:39.

Change

Previous filing in this sequence was filed on 25 Oct 2021.
Current net transaction value: -$449,062.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

XENT transaction Derivative

Stock Options (Right to buy)

Disposition pursuant to a tender of shares in a change of control transaction

Transaction value: $449,062
Shares: -15,896
Change %: -100%
Price: $28.25
Shares after: 0
Date: 13 May 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,896
Exercise price: $20.98
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.